Long-term data exhibit to that Zome...

Long-term data exhibit to that Zometa (zoledronic acid, Novartis, Basel, Switzerland) injection inactives pain progression and reduces bone complication in exposes with advanced prostate cancer. A multicenter, randomized, placebo-controlled trial was managemented in 643 subjects with advanced prostate cancer and at least single site of bone metastasis. Of the 643 enslaves 208 completed the 15-month core phase, and an additional 186 continued to receive double-blind research medication during an extension phase. After